Skip to main
NXTC
NXTC logo

Nextcure (NXTC) Stock Forecast & Price Target

Nextcure (NXTC) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

NextCure Inc has secured global rights to SIM0505 outside Greater China, with the potential for up to $745 million in upfront and milestone payments, alongside tiered royalties that could reach double-digit percentages on net sales. Recent preclinical data revealed promising anti-tumor efficacy across various solid tumor models and indicated a favorable safety profile, supporting the company's pipeline of cancer immunomedicines. Additionally, NextCure's strategy to advance multiple clinical and preclinical programs, including ADCs and partnerships for ongoing trials, positions the company for significant future growth in the biopharmaceutical market.

Bears say

NextCure Inc has seen a significant reduction in its projected enterprise value, now estimated at $37.5 million, down from a previous valuation of $75 million. This decline has led to a decrease in the projected price target to $15, reflecting concerns about the company's ability to successfully advance its therapies in clinical settings. Additionally, the potential failure of NextCure's therapies in clinical trials poses a substantial risk to the company's financial outlook and overall market confidence.

Nextcure (NXTC) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Nextcure and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Nextcure (NXTC) Forecast

Analysts have given Nextcure (NXTC) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Nextcure (NXTC) has a Strong Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Nextcure (NXTC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.